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E-mail: adalberto.vieyra@biof.ufrj.brHypertension is a long-term condition that can increase organ
susceptibility to insults and lead to severe complications such as
chronic kidney disease (CKD). Extracellular vesicles (EVs) are
cell-derived membrane structures that participate in cell-cell
communication by exporting encapsulated molecules to target
cells, regulating physiological and pathological processes. We
here demonstrate that multiple administration of EVs from
adipose-derived mesenchymal stromal cells (ASC-EVs) in
deoxycorticosterone acetate (DOCA)-salt hypertensive model
can protect renal tissue by maintaining its filtration capacity.
Indeed, ASC-EVs downregulated the pro-inflammatory mole-
cules monocyte chemoattracting protein-1 (MCP-1) and plas-
minogen activating inhibitor-1 (PAI1) and reduced recruit-
ment of macrophages in the kidney. Moreover, ASC-EVs
prevented cardiac tissue fibrosis and maintained blood pres-
sure within normal levels, thus demonstrating their multiple
favorable effects in different organs. By applying microRNA
(miRNA) microarray profile of the kidney of DOCA-salt rats,
we identified a selective miRNA signature associated with
epithelial-mesenchymal transition (EMT). One of the key path-
ways found was the axis miR-200-TGF-b, that was significantly
altered by EV administration, thereby affecting the EMT
signaling and preventing renal inflammatory response and
fibrosis development. Our results indicate that EVs can be a
potent therapeutic tool for the treatment of hypertension-
induced CKD in cardio-renal syndrome.
INTRODUCTION
Hypertension (HTN) is a complex multifactorial disease that results
in raised blood pressure and represents a comorbidity factor for the
development of cardiovascular and kidney diseases.1–3
In the kidney, long-termHTN can lead to the increase of intraglomer-
ular pressure, glomerular damage, and impairment of the filtrationMolecular Therapy: Methods &
This is an open access article under the CC BY-NCprocess. As a consequence, adaptive changes in nephrons occur to
compensate the initial damage, possibly leading to profibrotic mal-
adaptive modifications, loss of nephrons, and, consequently, to a
faster decline in the kidney functions.4 Moreover, the fibrotic process
is associated with the release of inflammatory mediators and recruit-
ment of inflammatory/immune cells that contribute to chronic kid-
ney disease (CKD).5 Although the kidney has an intrinsic regenerative
capacity, chronic conditions limit its ability to recover from insults.6
Regarding the cardiovascular system, progressive HTN drastically in-
duces cardiac changes that include cardiac hypertrophy and fibrosis,
ultimately causing myocardial stiffening and expansion, together with
deterioration of the heart electrical conduction and vascular hypertro-
phy and dysfunction.7 Moreover, in hypertensive patients the devel-
opment of cardiac damage has been associated with the overactivity of
the renin-angiotensin-aldosterone system.8
In addition to causing direct cardiac and renal injury, HTN also pre-
disposes patients to the so-called “cardio-renal syndrome” (CRS),
which refers to various conditions where dysfunction of either the
heart or kidneys leads to dysfunction of the other organs.9–11
Although its pathogenesis is not fully understood, several experi-
mental models have been developed to investigate the multiple factors
associated with CRS.12Clinical Development Vol. 16 March 2020 ª 2019 The Authors. 63
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of the TimeCourse of the Experimental
Protocol
Rats were subjected to unilateral nephrectomy (left kidney) at the age of 8 weeks
(first vertical line), and after 1 week were divided in the following experimental
groups: (1) uninephrectomized rats with standard-salt diet chow (UNX, n = 10); (2)
UNX with high Na+ diet plus DOCA twice a week (DOCA, n = 16); UNX with high salt
plus DOCA injected i.v. weekly with EVs (DOCA-EV, n = 10). Animals were moni-
tored weekly for systolic blood pressure (SBP). For the sake of clarity, only the first
administration of DOCA and EVs are indicated. Urine samples were collected every
2 weeks (vertical lines indicated as Urine) from weeks 9–17, and terminal blood
pressure, urine, and blood collection were finally performed at the time of sacrifice
(last vertical line). A 4th group of Sham (false operated) rats that received standard-
salt diet was also analyzed (SHAM, n = 8).
Molecular Therapy: Methods & Clinical DevelopmentThe deoxycorticosterone acetate (DOCA)-salt model provides an
imbalance of renal Na+ handling due to the administration of the
aldosterone precursor DOCA, which increases Na+ and water reab-
sorption by the distal nephron, promoting hypervolemia and conse-
quently inducing hypertension.13 Administration of a high-salt diet in
combination with uninephrectomy also drastically increases the onset
of hypertension.13 An overactive sympathetic nervous system seems
to have a central role in the development of hypertension in
DOCA-salt rats, raising blood pressure through its direct effect on
venous smooth muscle tone and peripheral vascular resistance.14 As
a result, DOCA-salt treated animals provide a chronic vascular re-
modeling, with development of hypertrophy, fibrosis, and inflamma-
tory cell infiltration in the heart and the kidney,15,16 along with acti-
vation of renal transforming growth factor b (TGF-b) expression.17
The potential benefit of mesenchymal stromal cells (MSCs) in the
treatment of kidney diseases has been widely studied.18 Among the
different sources of MSCs, adipose tissue is an easy and repeatable
harvested source. Adipose-derived mesenchymal cells (ASCs) have
immunosuppressive properties, low immunogenicity and secrete tro-
phic factors that support tissue regeneration.19
The main mechanism of action of bone marrow and tissue MSCs
has been attributed to the secretion of extracellular vesicles (EVs),mem-
brane structures that carry bioactive molecules (proteins, lipids, and64 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchnucleic acids) regulating different cellular processes in the recipient
cells.20The beneficial effects ofMSC-EVs in different pathological states
are associated with reduction of inflammatory infiltrate and decrease of
fibrosis, which represent important processes also in CKD pathophys-
iology.21 An important role of MSC has been shown in EVs by limiting
acute to chronic kidney injury transition and progression.22–24
We have tested the hypothesis that ASC derived EVs (ASC-EVs) can
positively modulate the development of CKD by affecting inflamma-
tion and fibrosis in the cardio-renal system in DOCA-salt treated rats.
In view of the importance of microRNA (miRNAs) in these processes,
we have also evaluated the possible involvement of a specific kidney
miRNAs signature in DOCA-salt induced CRS and the impact of
EVs on these pathways.
RESULTS
Characterization of ASC-EVs
ASCs cultured for 72 h in EVs collection medium were analyzed by
transmission electronmicroscopy (TEM) (Figure S1A).Vesicular struc-
tures of different sizewere detected on the surface of the cells, indicating
the existence of active release of EVs fromASCs (Figure S1A). EVswere
collected from ASCs as described in the Materials and Methods and
their presence was confirmed by TEM (Figure S1B). EVs are heteroge-
neous in size and comprise small and large size vesicle populations.
Nanoparticle tracking analysis (NTA) was used to characterize and
count EVs,which in this casewas a heterogeneous pattern (Figure S1C),
with a mean size distribution of 114.1 ± 8.6 nm and a mean value of
5,752 ± 487 particles released for each cell (EV preparations, n = 10).
Flow cytometry analysis showed the expression by ASC-EVs of the exo-
some markers CD63 and CD81, but not CD9 (Figure S1D).
ASC-EV Treatment Prevent the Progressive Increase of Blood
Pressure in DOCA-Salt Rats
We evaluated the effect of ASC-EV administration in the hypertensive
rat model DOCA-salt (Figure 1). With respect of UNX rats, the DOCA
animals (treated with DOCA-salt) lost significant body weight (Fig-
ure 2A) after 8 weeks from the unilateral nephrectomy (p < 0.05).
The nephrectomy procedure (UNX) did not affect body weight as de-
tected by the comparison with control Sham rats (SHAM, Figure 2A).
Systolic blood pressure (SBP) was recorded before and 1 week after un-
inephrectomy; no modification was observed in rats submitted to the
surgical procedure (133.6 ± 2.7 versus 135.3 ± 4.0 mmHg, before and
after nephrectomy, respectively). The SBP was measured every week
for 8 weeks and a steadily increase in DOCA animals was recorded dur-
ing the entire treatment period (Figure 2B). By week 4, SBP was signif-
icantly elevated in DOCA-salt animals compared to UNX and SHAM
rats (p < 0.05 versus control animals). However, weekly injections of
EVs from week 2 after nephrectomy in DOCA rats (DOCA-EV),
were able to alleviate any further increase in SBP induced by DOCA-
salt treatment from week 5 from nephrectomy. This pressure profile
wasmaintained until sacrifice, indicating that EV treatment couldmiti-
gate the increase in DOCA-salt induced SBP. At week 9, the DOCA
group had the highest SBP and diastolic blood pressure (DBP), which2020
Figure 2. ASC-EVs Normalized Hypertension and
Prevented CKD Progression in DOCA-Salt Rats
(A) Body weight was measured in DOCA-salt treated rats
at time of sacrifice (week 9) and compared with untreated
UNX animals (UNX, n = 9; DOCA, n = 13; DOCA-EV, n =
10). A group of false operated animals was also analyzed
(SHAM, n = 8). (B) SBP of DOCA rats were recorded every
week after nephrectomy (UNX) for 8 weeks (1–8 weeks)
and compared with untreated UNX animals and SHAM
animals. The value of SBP reported is the mean of blood
pressure of all the animals tested in each experimental
group at each time point (SHAM, n = 4; UNX, n = 9; DOCA,
n = 13; DOCA-EV, n = 10). SBP (C) and diastolic blood
pressure (DBP) (D) were recorded before sacrifice (week 9)
for all the animals tested in the 4 experimental groups
(number of animals, n = 8–13). (E) Measure of creatinine
clearance (CrC) normalized for body weight and ex-
pressed as mL/min/100 g measured for all the animals
tested in the 4 experimental groups (number of animals,
n = 8–13). (F) Time course of 24 h-protein urinary excretion
(mg/24 h) before nephrectomy until sacrifice (SHAM, n =
4; UNX, n = 9; DOCA, n = 13; DOCA-EV, n = 10). All data
represent mean ± SE. *indicates statistical difference to
SHAM group; # indicates statistical difference to UNX
group, x indicates statistical difference to DOCA-EV
group; p < 0.05.
www.moleculartherapy.orgwere indeed reduced in EV-treated DOCA animals (Figures 2C and
2D). EV treatment did not affect reduction of body weight induced by
DOCA-salt at time of sacrifice (Figure 2A).
ASC-EVs Improved Renal Function Parameters and Decreased
Urinary Protein Excretion in DOCA-Salt Rats
Time-course analysis of 24 h-water consumption indicated a signif-
icant increase in this parameter in DOCA animals at week
3 after nephrectomy with respect to SHAM and UNX animals
(110.6 ± 1.3, 28.4 ± 0.2, and 44.83 ± 1.5, respectively, p < 0.05 in
respect to controls). The same was observed for the urinary volume
(12.7 ± 0.1, 3.3 ± 0.3, and 3.5 ± 0.2, respectively, p < 0.05 in respect
to controls). EV treatment transiently ameliorated the polyuria state
of DOCA rats as measured by the urinary volume at weeks
3 (DOCA-EV, 10.3 ± 0.4, p < 0.05 in respect to DOCA) and
5 (DOCA, 10.68 ± 0.1 and DOCA-EV, 8.33 ± 0.1, p < 0.05 in
respect to DOCA) but it had no effect at later time points (data
not shown). As illustrated in Table S1, together with the 24 h-uri-
nary volume, Na+ excretion at week 9 was significantly increased
in DOCA rats compared to SHAM and UNX animals, which wasMolecular Therapy: Methods &not modified by the EV treatment. All the 3
treated groups showed a significant reduction
in K+ excretion compared to SHAM rats,
with no difference between them (Table S1).
The impact of increased systemic HTN on renal
functionwas subsequently investigated, including
proteinuria development and the effect of EV
administration. There was a significant increasein plasma creatinine levels (Table S1) together with a significant reduc-
tion in the creatinine clearance in DOCA rats with respect to UNX
(30%) and SHAM animals (~50%) (Figure 2E). EV treatment restored
normal plasma creatinine levels and a creatinine clearance similar to the
UNX rats. In parallel, hypertensive DOCA animals developed progres-
sive proteinuria compared to SHAM and UNX animals, reaching a sig-
nificant increase at week 9, measured by 24 h protein excretion levels
(Figure 2F) and as the urinary protein/creatinine ratio (UP:Cr; Table
S1). As for functional parameters, ASC-EV treatment significantly
reduced 24 h protein excretion (Figure 2F) and the UP:Cr ratio (Table
S1) inDOCAsalt-treated animals, supporting the view that EVs actively
protect against kidney damage. Hypertensive rats also developed albu-
minuria, which was expressed as the urinary albumin/creatinine ratio
(UA:Cr, Table S1). ASC-EV treatment significantly decreased albumin-
uria in DOCA animals (Table S1).
ASC-EVs ImprovedMorphology and ReducedClassical Markers
of Kidney Damage in DOCA-Salt Rats
Besides the examination of biochemical parameters, renal damage
was then quantified with respect to renal hypertrophy and byClinical Development Vol. 16 March 2020 65
Figure 3. ASC-EV Treatment Improved Morphology
and Reduced Classical Markers of Kidney Damage
in DOCA-Salt Rats
(A) Representative image of a transverse section of the
entire kidney stained with H&E of 9-week-treated rats
under different experimental conditions, as indicated at the
top of the panels. (B) Right kidney weight normalized by
the body weight (mg/g) of 9-week-treated rats measured
for all the animals tested in the 4 experimental groups
(SHAM, n = 4; UNX, n = 9; DOCA, n = 13; DOCA-EV, n =
10). (C) Representative photomicrographs of the kidney
cortex showing glomerular (upper images) and tubular
structures (lower images) in kidney sections from the 4
groups, as indicated in the top of the panels. H&E was
used as staining (scale bars, 50 mm). Black arrows indicate
inflammatory cells infiltration; red arrows indicate tubular
dilation; blue arrows indicate extracellular matrix expan-
sion and glomerulosclerosis. (D and E) Histological score
of tubular (D) and vascular (E) lesions of the kidneys of all
the animals tested in the 4 experimental groups (SHAM,
n = 4; UNX, n = 9; DOCA, n = 13; DOCA-EV, n = 10),
quantified as described in the Materials and Methods
section. (F and G) KIM-1 (F) and NGAL (G) mRNA levels in
the renal tissue of SHAM (n = 3) and in the unin-
ephrectomized groups (UNX, n = 6; DOCA and DOCA-EV,
n = 7). Quantitative real-time PCR data were expressed as
relative quantification (RQ) and UNX was used as the
reference sample. Data represent mean ± SE. *indicates
statistical difference to SHAM group, # indicates statistical
difference to UNX group, and x indicates statistical differ-
ence to DOCA-EV group; p < 0.05.
Molecular Therapy: Methods & Clinical Developmenthistological analysis. Figure 3A shows that kidneys had accentuated
hypertrophy provoked by DOCA-salt treatment, which was amelio-
rated by EV administration. There was also a significant difference
in the kidney-to-body weight ratio between DOCA and both
SHAM and UNX rats (11.9 ± 0.07 versus 4.0 ± 0.09 and 5.4 ± 0.08,
respectively; Figure 3B). ASC-EV treatment resulted in a modest
(20%), but significant, reduction in the kidney-to-body weight
compared with DOCA (p < 0.05). H&E staining showed increased
tubular damage (including atrophy, loss of brush border, and
presence of protein casts), along with an accumulation of interstitial
matrix and evidence of inflammation in the cortex of DOCA rats
compared to SHAM and UNX controls (Figure 3C), which were
ameliorated in EVs-treated rats.
The quantitative measure of tubular damage was higher in DOCA rats
(6.3 ± 0.33) with very slight injury in the UNX group (0.7 ± 0.21; Fig-
ure 3D). DOCA rats also developed vascular damage (3.1 ± 0.07),
which was very low in the UNX group (0.9 ± 0.01), with no such signs
being seen in SHAM animals (Figure 3E). DOCA-EV rats showed
significantly less tubular and vascular damage (4.7 ± 0.69 and 2.2 ±
0.04, p < 0.05 compared toDOCA). The degree of injurywas confirmed
by measuring expression of 2 markers of kidney injury, namely kidney
injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipo-
calin (NGAL) (Figures 3F and 3G). Compared to the other experi-
mental groups, the DOCA animals expressed 20-fold higher levels of66 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchKIM-1 and NGAL (p <0.05) in the kidney, but EV treatment signifi-
cantly reduced these values (Figures 3F and 3G).
To measure the presence of proliferating cells, we used immunohisto-
chemistry for proliferating cell nuclear antigen (PCNA) (Figure S2A).
PCNA-positive cells occurred in DOCA rats, in the interstitial tissue
and in the tubules, both in the cortical region (excluding glomeruli)
and inner medulla (Figure S2A). Also in this case, EV treatment
markedly attenuated (~50%) cell proliferation in the cortical and
medullary areas of the kidney (Figure S2B).
The effects of DOCA-salt treatment on apoptosis were also examined
by determining the ratio of pro-apoptotic protein Bax to the anti-
apoptotic protein Bcl-2 (Figure S2C). The Bax/Bcl-2 protein ratio
increased 100% in the kidneys of DOCA rats compared with UNX
animals, whereas the EV treatment reversed the ratio to the levels
of the control rats.
ASC-EVs Attenuated Renal Fibrosis in Rats Induced by DOCA-
Salt Treatment
Analysis of renal fibrosis by Picrosirius red staining indicated the
presence of collagen deposition in the kidneys of hypertensive rats,
primarily in the interstitial space (Figure 4A). Figure 4B shows kidney
immunostaining of alpha-smooth muscle actin (a-SMA), a marker
of myofibroblasts. In SHAM and UNX rats, positive physiological2020
Figure 4. ASC-EV Treatment Promoted Important Attenuation of Kidney Fibrosis in the DOCA-Salt Model
(A) Representative photomicrographs of kidney slices stained with Picrosirius red on 9-week-treated rats from the 4 experimental groups (scale bars, 50 mm). (B)
a-SMA expression in the kidney of 9-week-treated rats under the different experimental conditions was determined by immunohistochemistry (n = 4 for each
treatment) (scale bars, 50 mm). (C) Quantification of Picrosirius red stained area in kidney sections expressed as a percentage of the total area of the kidney, in
9-week-treated rats, measured for all the animals tested in the 4 experimental groups (SHAM, n = 4; UNX, n = 9; DOCA, n = 13; DOCA-EV, n = 10). (DF) Western
blot analysis of a-SMA and Desmin in the cortex of 9-week-treated UNX (n = 6), DOCA, and DOCA-EV (n = 8) rats. GAPDH was used as loading control. Values
represent the fold increase with respect to UNX (considered as the reference = 1). (GI) Analysis of COL1A1, COL4A1, and FN mRNA levels in the renal tissue in
control SHAM (n = 3) and in all the uninephrectomized animal groups (UNX, n = 6; DOCA and DOCA-EV, n = 7). qRT-PCR data were expressed as RQ and UNX was
used as the reference sample. Data represent mean ± SE. *indicates statistical difference to SHAM group, # indicates statistical difference to UNX group, and x
indicates statistical difference to DOCA group; p < 0.05.
www.moleculartherapy.orgstaining of a-SMA was found only in the blood vessels (Figure 4B),
whereas a-SMA was localized in the interstitial and periglomerular
regions in DOCA rats. Quantification of the Picrosirius red staining
demonstrated an increase in collagen deposition by 100% in the kid-
neys of DOCA rats, that was absent in DOCA-salt rats treated with
ASC-EVs (Figure 4C). Moreover, a-SMA expression was significantly
increased in the kidney of DOCA rats compared to the UNX, as de-
tected by western blotting analysis (Figures 4D and 4E). EV treatment
of DOCA rats reduced expression of a-SMA (Figures 4D and 4E),
which had localized similarly to that seen in UNX rats (Figure 4B).MoleculWe also detected a significant increase in the glomerular damage
marker, Desmin, in DOCA rats, which was almost absent in UNX
and DOCA-EV animals (Figures 4D and 4F). Glomerular lesions
were detected in DOCA animals by quantitative measure of the
glomerular damage score (1.7 ± 0.03, for DOCA), which was signifi-
cantly reduced in both the UNX and DOCA-EV groups (0.9 ± 0.01
and 1.3 ± 0.07, p <0.05). These structural improvements induced
by the EV treatment were accompanied by a decrease in the gene
expression of profibrotic collagens (Col1A1, Col4A1) and fibronectin
(FN1) genes (Figures 4G–4I).ar Therapy: Methods & Clinical Development Vol. 16 March 2020 67
Figure 5. ASC-EVs Have Accentuated Anti-Inflammatory Properties in the DOCA-Salt Model
(A) Representative photomicrograph of ECD68 macrophage cell-surface marker expression determined by immunohistochemistry in the kidneys of 9-week-treated rats
under the experimental conditions indicated at the top of the panels (scale bars, 50 mm). (BE) Analysis ofCD68 (B), PAI1 (C),MCP-1 (D), and IL-6 (E) mRNA levels in the renal
tissue in control SHAM (n = 3) and in all the uninephrectomized animals (UNX, n = 6; DOCA and DOCA-EV, n = 7). qRT-PCR data were expressed as RQ and UNX was used
as reference sample. Data represent mean ± SE. *indicates statistical difference to SHAM group, # indicates statistical difference to UNX group, and x indicates statistical
difference to DOCA-EV group; p < 0.05.
Molecular Therapy: Methods & Clinical DevelopmentASC-EVs Reduced the Expression of Pro-Inflammatory
Cytokines and Macrophage Infiltration of the Kidney
Immunohistochemical staining of cluster of differentiation 68 (CD68),
a specific macrophage cell-surface marker, showed massive macro-
phage infiltration in response to DOCA-salt treatment (Figure 5A).
The increased accumulation of CD68 in the renal interstitial space of
DOCA rats was also quantitatively confirmed at the mRNA level by
6-fold, showing that EV treatment reduced gene expression of CD68
to levels that were no different from that of control animals (Figure 5B).
In DOCA rats, EVs were also effective in reducing the mRNA expres-
sion of the plasminogen activator inhibitor-1 (PAI1) and the inflamma-
tory molecules monocyte chemoattracting-1 (MCP-1) and interleukin-
6 (IL-6) (Figure 5C–5E).ASC-EVs AttenuatedCardiac Fibrosis in Rats Induced by DOCA-
Salt Treatment
As in the case of the kidney, cardiac fibrosis was drastically increased
in DOCA rats, with accumulation of interstitial and perivascular
collagen, as determined by Masson’s trichrome (Figure 6A) and
Picrosirius red staining (Figure 6B). An increase of cardiac fibrosis
was associated with inflammation in the heart, detected by the pres-
ence of foci of CD68-positive macrophages in DOCA rats (Figure 6C).
Fibrosis and infiltrating macrophages were significantly attenuated by
treatment with EVs, confirmed by quantitative analyses (Figures 6D
and 6E). Hypertensive DOCA-treated rats had cardiac hypertrophy,
which was absent in the normotensive SHAM and UNX animals,
measured by the heart index (heart weight/body weight ratio;
DOCA, 4.8 ± 0.02; SHAM, 3.6 ± 0.04; and UNX, 3.3 ± 0.01, respec-
tively). In this case, the EV treatment also lowered the heart-to-body68 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchweight ratio in DOCA rats (4.4 ± 0.02, p < 0.05), but it remained
higher than controls (Figure 6F).DOCA-Salt Treatment Modulates miRNA Expression in the
Renal Lesions
To test the hypothesis that renal fibrosis and inflammation in DOCA-
salt can be associated with a distinctive miRNA signature, we
screened renal samples from SHAM, UNX, DOCA, and DOCA-EV
rats for the expression of 758 mature rodent miRNAs. A total of
553 miRNAs were detected in at least 3 of 4 renal samples (80%)
analyzed among the entire mature rodent miRNA panel. Hierarchical
clustering analysis of all the groups highlighted the generation of
5 different clusters of expression (Figure 7A). Moreover, fold-change
analysis indicated that 149 miRNAs were differentially expressed be-
tween DOCA rats and all the other 3 experimental groups (Table S2).
EV treatment induced modification of the miRNA signature in
DOCA-salt treated rats, with 56 miRNAs being upregulated (Fig-
ure 7B, upper part) and 19 downregulated (Figure 7B, lower part)
in DOCA-EV with respect to DOCA rat kidneys. Of interest, 36
upregulated and 14 downregulated miRNAs in DOCA-EV were
commonly found in UNX-treated rats only, highlighting that, after
EV treatment, the miRNA signature of DOCA-salt rats was restored
toward the changes found in nephrectomized rats that had no signs of
renal injury.
Aiming to define the differential molecular signature between DOCA
and the groups UNX and DOCA-EV, we conducted in silico analysis
of the differentially expressed miRNAs. Starting from input miRNAs,2020
Figure 6. ASC-EVs Markedly Attenuated Cardiac Fibrosis Induced in Rats by DOCA-Salt Treatment
(A and B) Representative photomicrographs of heart slices stained with Masson’s trichrome and Picrosirius red of 9-week-treated rats of the different experimental groups
indicated at the top (scale bars, 50 mm). (C) Representative photomicrograph of CD68 marker expression determined by immunohistochemistry in the heart of 9-week-
treated rats under the different experimental conditions (scale bars, 50 mm). (D) Quantification of Picrosirius red staining area expressed as a percentage of total area of the
heart in 9-week-treated ratsmeasured for all the animals in the 4 experimental groups (SHAM, n = 4; UNX, n = 9; DOCA, n = 13; DOCA-EV, n = 10). (E) Quantification of CD68-
positive area expressed as a percentage of positive area/field (10 fields/animal), determined by immunohistochemistry in the heart of 9-week-treated rats (n = 4 animals for
each treatment). (F) Heart weights with respect to body weight (mg/g) of 9-week-treated rats of each experimental group measured for all the animals tested in the 4
experimental groups (SHAM, n = 4; UNX, n = 9; DOCA, n = 13; DOCA-EV, n = 10). Data represent mean ± SE. *indicates statistical difference to SHAM group, # indicates
statistical difference to UNX group, and x indicates statistical difference to DOCA group; p < 0.05.
www.moleculartherapy.orgit was possible to identify predicted and validated target genes and
categorize them to produce representative pathway maps.25 The pro-
cesses associated with these genes are related to cellular response to
amino acids and chemical stimulus, including a wide ensemble of
cellular responses to different oxygen- and nitrogen-containing
compounds (Figure 7C).
Interestingly, the most representative network of the common differ-
entially expressed miRNAs was associated with the development and
regulation of epithelial-mesenchymal transition (EMT; Figure 8A).
ThemiR-200 familymembers and their direct target nodes were high-
lighted as overrepresented elements involved in DOCA-salt treatment
(Figure 8A). To validate these data, we further analyzed miR-200a-3p,Molecul-200b-3p, -200c-3p, -141 and -429 in the kidneys by quantitative real-
time PCR; their expression levels were significantly lower in the
DOCA groups than those in the controls (SHAM and UNX). EV
treatment reversed the DOCA-salt regulation in all the miR-200 fam-
ily investigated, also upregulating miR-200c-3p, which was unmodi-
fied in DOCA and control samples (Figure 8B).
ASC-EVs Downregulated Profibrotic Genes in DOCA-Salt
Treated Rats
Direct nodes of the miR-200 family were the zinc finger E-box bind-
ing homeobox 1 (ZEB1) and 2 (ZEB2), also known as TCF8 and SIP1,
respectively. Expression of TCF8 and SIP1 was significantly elevated
in DOCA-salt treated animals with respect to SHAM (Figures 8Car Therapy: Methods & Clinical Development Vol. 16 March 2020 69
Figure 7. A Healing miRNA Signature Was
Generated by ASC-EV Administration
(A) Hierarchical clustering analysis of the 553 rat miRNAs
expressed in the kidney of 9-week-treated rats under the
different experimental conditions (SHAM, UNX, DOCA,
and DOCA-EV groups, n = 2 for each condition from 4
animals/group). (B) Venn diagrams of the upregulated
(upper panel) and downregulated (lower panel) miRNAs in
the kidneys of the UNX and DOCA-EV groupswith respect
to DOCA. The diagrams show the commonly or selectively
modulated miRNAs. (C) Significantly enriched biological
processes associated with the identified target genes of
the differentially expressed miRNAs in DOCA animals with
respect to UNX or DOCA-EV, indicated by the marks/
colors of the horizontal bars (blue and white, common
miRNAs; red, DOCA-EV selective; blue, UNX selective).
Molecular Therapy: Methods & Clinical Developmentand 8D). EV treatment reduced the upregulation of these genes
after DOCA-salt treatment to the levels of UNX renal specimens
(Figures 8C and 8D; p <0.05). Other pro-fibrotic genes directly or
indirectly connected with the miR-200 family and involved in
EMT, such as connective tissue growth factor (CTGF), TGF-b1, and
TGF-b2, were then tested. DOCA-salt treatment induced a strong
upregulation of all these EMT genes, whereas EV administration
had the opposite effect (Figures 7E–7G). The zinc-finger-containing
transcription factors Slug 1 and 2 (SNAI1 and SNAI2) are known to
repress transcription of E-cadherin and stimulate vascular endothelial
cadherin and fibronectin genes.26 Quantitative real-time PCR showed
a stimulatory effect of DOCA-salt treatment on SNAI1 and SNAI2
mRNA, which was totally blocked by EV treatment (Figures 8H
and 8I). Together with the enhancement of TGF-b1 expression, the
DOCA-salt treatment also induced upregulation of miR-155-5p, an
important miRNA associated with EMT; again, upregulation of
miR-155-5p was abrogated by EVs (Figure 8J).
DISCUSSION
Wehere demonstrate thatmultiple administration of ASC-EVs in a hy-
pertensive-induced CKD model promotes protection from renal dam-
age, conservation of renal function, reduction of the inflammatory
response, and prevention of interstitial fibrosis in the kidney. ASC-
EVs also prevented fibrosis in cardiac tissue and maintained the blood
pressure within normal levels, displaying complex and multiorgan
beneficial effects in the complex pathophysiology of DOCA-salt-
induced CRS. We also identified a distinctive EMT miRNA signature70 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020induced by DOCA treatment that directly corre-
lated with increased TGF-b gene expression and
renal damage. All of these molecular modifica-
tions were reversed by ASC-EV administration.
Renal damage and TGF-b upregulation are also
associated in diseases, such as diabetes.27
CKDis characterizedby several structural changes
in the kidney that result in a progressive loss of
nephrons and renal function.28 The DOCA-saltmodel mimics a multifactorial pathological state associated with CKD.
Although it presents some limitations to represent the entire complexity
of chronic disease, the model encloses several aspects, including the in-
crease in blood pressure, kidney and heart hypertrophy, renal tubular
and vascular damage, and extensive development of fibrosis.
Different studies reported the engagement of several primary mech-
anisms of hormonal, renal, and neural origin as a requirement for
the raising of blood pressure observed in this model.29 In the kid-
ney, the retention of Na+, and subsequently of water, as an attempt
to maintain plasma osmolality, distinctly participates in DOCA-salt
hypertension.30,31 Moreover, the high Na+ diet load for 8 weeks
together with injection of DOCA, results in severe HTN, strongly
interconnected with renal function deterioration and glomerular
damage, as indicated by the development of proteinuria and reduc-
tion of the creatinine clearance.32 We also observed that long-term
induced HTN causes tubular injury and microvasculature rarefac-
tion, inducing renal damage in DOCA-salt rats. This was accompa-
nied by a strong induction of pro-oxidative processes associated
with the upregulation of the pro-apoptotic protein, Bax, and the
downregulation of the anti-apoptotic protein, Bcl-2—a prelude to
cell death.33
Previous observations demonstrated the anti-fibrotic effects of EVs
derived from different MSC types (bone-marrow derived, adipose-tis-
sue derived, and liver derived) in different CKD models.34–36 Our an-
alyses for the first time show the effect of ASC-EV treatment in a
Figure 8. ASC-EVs Modulated miRNAs Associated with TGF-b-Dependent EMT and Fibrosis
(A) EMT pathway network generated by the overrepresented target-miRNA interactions built from the list of miRNAs modulated in UNX and DOCA-EV compared to DOCA
rats. (B) Validation by quantitative real-time PCR of the expression of miR-200 family members in SHAM (n = 3) and in all the uninephrectomized animals (UNX, DOCA, and
DOCA-EV, n = 6). (C–I) Analysis of the mRNA expression levels of the direct nodes of the miR-200 family TCF8 (C) and SIP1 (D), and the pro-fibrotic genes CTGF (E), TGF-b1
(F), TGF-b2 (G), SNAI1 (H), and SNAI2 (I) in the cortical tissue from SHAM (n = 3) and in all the uninephrectomized animal groups (UNX, n = 6; DOCA and DOCA-EV, n = 7). (J)
miR-155-5p expression levels in the kidney from SHAM (n = 3) and in all the uninephrectomized animal groups (UNX, DOCA, and DOCA-EV, n = 6). Quantitative real-time
PCR data were expressed as RQ and UNXwas used as the reference sample. Data represent mean ± SE. *indicates statistical difference to UNX group, # indicates statistical
difference to UNX group, and x indicates statistical difference to DOCA-EV group; p < 0.05.
www.moleculartherapy.orgcomplex andmultitarget disease, dissecting the effect of EV administra-
tion on kidney-heart co-morbidity in the context of hypertension. We
found that the beneficial effects of EVs covered multiple tissue/organs
and could be ascribed to some a vascular protection mechanism,
together with a tissue-protecting effect at both renal and heart levels.
In our DOCA model, multiple administrations of ASC-EVs could in
the first instance control the rise in the SBP, thus preventing any furtherMoleculincrease from week 5 until sacrifice. Although it is difficult to dissect
out the precise mechanism involved in the amelioration of SBP in
EV-treated rats, we have speculated that ASC-EVs directly counterbal-
ance hypertension by protecting the vasculature. This result is consis-
tent with the effect reported forMSC-EV intravenous (i.v.) administra-
tion on the amelioration of pulmonary pressure and right ventricular
pressure in a model of pulmonary hypertension.37ar Therapy: Methods & Clinical Development Vol. 16 March 2020 71
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been previously associated with reduction of sympathetic activity
affecting the cardiovascular system in a neurological model of hy-
pertension.38 Such modulation also resulted in the improvement
of the renal architecture and microvascular rarefaction in the
MSC-treated animals, suggesting that the regulation of SBP by
ASC-EVs depends not only on a vascular effect but on a nervous
system regulatory component.38 In addition, 8-week-DOCA-treated
animals had kidney and heart hypertrophy, indicating renal vasodi-
latation and cardiac overgrowth as a response to the high Na+ load.
Their excess weight was significantly reduced by EV treatment, sug-
gesting the promotion of positive compensatory effects at tissue
levels.
In concomitance with hemodynamic regulation, EV treatment pro-
moted other beneficial effects to tissues, associated perhaps with
anti-fibrotic mechanisms. ASC-EV administration reduced kidney
damage, indicated by the decline of the renal injury score and
KIM-1 and NGAL expression. These markers associated with renal
tubular injury were upregulated by DOCA treatment. KIM-1 is a
cell-surface receptor that is upregulated in AKI and CKD. Increase
in KIM-1 expression in CKD is associated with maladaptive response
of renal tissue, stimulating inflammation and fibrosis.39 NGAL is
another important marker and a strong predictor of unfavorable renal
outcomes and progression in CKD,40 being directly correlated with
declining renal function.41 Reduction of both markers after ASC-
EV administration underlines their protective effects on tubular pro-
cesses. In addition, the protective effect of ASC-EVs was accompanied
by reduction in renal accumulation of the marker of podocyte dam-
age, Desmin,42 and of the glomerular lesions observed in DOCA
rats. All the protective effects of ASC-EVs on different nephron struc-
tures resulted in maintenance of kidney function at the same levels as
uninephrectomy animals, indicated by our measurements of plasma
creatine levels, normalized creatinine clearance, and proteinuria.
The tissue-protecting effect of EVs was confirmed on different aspects
of the profibrotic mechanisms, including renal apoptosis, increased
cell proliferation, inflammation, collagen, and a-SMA accumulation,
resulting in a “global” amelioration of kidney functions.
ASC-EVs induced a strong immunomodulatory response that in-
hibited macrophage recruitment (CD68 positive cells) to the kidney.
This effect onmacrophage accumulation may depend on EV-induced
downregulation of PAI1 and MCP-1, which are both upregulated in
DOCA-salt rats. PAI1, a glycoprotein produced by resident and in-
flammatory cells, has a pro-fibrotic role and triggers a vicious cycle
based on the recruitment of other inflammatory cells and fibroblast
activation.43 MCP-1 together with IL-6, also upregulated by DOCA
treatment and reduced by EV administration, are multifunctional mi-
croinflammatory cytokines involved in immunoreaction and inflam-
mation in hypertensive kidney disease.44 Moreover, IL-6 is commonly
found at high levels in the plasma of CKD patients45 and has been
associated with CKD progression through a mechanism involving
promotion of renal injury and induction of chronic vascular disease.46
Interestingly, recent reports highlighted the hypertensive state in72 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchDOCA-salt mice as an inflammation progress, where the inflamma-
some deficiency induces a fall in high BP, along with reduction of
macrophages and pro-inflammatory cytokines in the kidneys
compared to controls.47 Chronic inflammation is not exclusive of
HTN, but of other disorders, such as cardiovascular diseases.48 Of
note, in our model the beneficial immunomodulatory effects of the
EV treatment were also seen in cardiac tissue, which had reduced
fibrosis and macrophage infiltration compared to untreated DOCA-
salt animals.
In order to understand the mechanisms associated with the therapeu-
tic effects of ASC-EVs, we focused on the analysis of the miRNA
signature in the renal tissue. Tissue and circulating miRNAs have
recently emerged as mediators of intercellular communication and
as potential biomarkers of cardiovascular and renal diseases.49,50
Kidneys from DOCA-salt rats have a specific signature in which the
most representative node was “development and regulation of
EMT.” The miR-200 family (miR-200a-3p, -200b-3p, -200c-3p,
-141, and -429) includes well-known factors in the regulation of the
EMT process.51 Recent studies showed that 3 members of the
miR-200 family (miR-200a-3p, miR-200b-3p, and miR-141) were
markedly downregulated in ureteral obstruction (UUO) kidneys,52
supporting their role in protecting tubular epithelial cells from
dedifferentiation and EMT. We found that several members of the
miR-200 family (miR-200a-3p, -200b-3p, -141, and -429) were down-
regulated by DOCA-salt treatment, and their expression reversed by
EV administration. Importantly, we also found that the expression of
several miR-200 family targets associated with the kidney fibrosis pro-
cess was significantly inhibited by ASC-EVs (SNAI1, SNAI2, TCF8,
CTGF, and SIP1). Of note, miR-200a-3p and -141 seem to impair pro-
gression of TGF-b-dependent EMT and fibrosis in vitro by direct
downregulation of TGF-b2 expression.53 In addition, the regulatory
effects of miR-200b-3p were confirmed by i.v. administration of its
synthetic precursor in UUO mice, thereby inhibiting the synthesis
of FN, collagen types I and III, and reducing renal tubulointerstitial
fibrosis.54 Interestingly, our data suggest that this mechanism modu-
lates the fibrotic process in DOCA-salt animals and that it represents
a specific target of the ASC-EV treatment, in which the molecular
content of EVs (proteins and RNAs) can activate an epigenetic modi-
fication able to directly modify the EMT and fibrosis pathways
through the regulation of the axis miR-200-TGF-b.
Because DOCA-salt mimics a multi-organ chronic disease, the defini-
tion of the first organs targeted by EVs after their injection and what
their immediate actions are could not be completely elucidated.
Studies evaluating the effect of MSC-EVs after a short time from
EV administration in AKI models have shown that EVs can promote
the reduction of cell death and oxidative stress response in renal
endothelial and epithelial cells.55,56 Further biodistribution studies
are necessary to encrypt these questions in chronic pathologies,
such as CRS, in which the organs affected by the damage are more
than one and targeted at different times. Moreover, our data sustained
the use of EVs as a pharmacological drug, supporting a life treatment
option for the patient affected by renal hypertension. Recently Braun2020
www.moleculartherapy.orget al.57 showed that multiple injections of MSC-derived exosomes in a
model of neonatal chronic bronchopulmonary dysplasia were able to
protect lung and heart from hyperoxia, preserving alveolar growth
and inhibiting right heart hypertrophy. Intriguingly, these data sup-
port the capability of EVs to prompt a beneficial effect, after that
the damage occurred independently from the first cause (hyperoxia)
and also without a continuation of the treatment.55 It is important to
mention that in our protocol, the administration of ASC-EVs was
maintained until the end of the treatment. Future experiments ceas-
ing the administration of the EVs could give further information
about the lasting EV effects in CKD models.
In conclusion, our results show that ASC-EVs administered in
multiple doses can be effective as a therapy for the treatment of
HTN and CRS, preventing CKD. Moreover, our findings indicate
that miRNAs, in particular those of the miR-200 family, play a central
role in CKD progression and evolution toward CRS, representing a
therapeutic option in hypertensive-induced CKD.
MATERIALS AND METHODS
Cell Culture
Human ASCs were purchased from Lonza (Basel, Switzerland) and
cultured in Adipose-Derived Stem Cell Growth BulletKit Medium
(Lonza) at 37C in a humidified atmosphere containing 5% CO2 in
air. Expression of classical ASCs surface markers allophycocyanin
(APC), phycoerythrin (PE), and fluorescein (FITC) isothiocyanate-
conjugated (CD44, CD90, CD73, CD105, all from BD Bioscience,
San Jose, CA, USA) were confirmed by flow cytometry analysis
(data not shown). As control, mouse isotypic immunoglobulin G
(IgG) conjugated antibodies were used (BD Bioscience).
Extracellular Vesicles Isolation and Characterization
Briefly, when the ASCs reached ~70% confluency, they were washed
twice with PBS and cultured in serum-free RPMI medium (Thermo
Fisher Scientific, Waltham, MA, USA) for 72 h at 37C in 5% CO2
in air atmosphere. The conditioned medium was collected and centri-
fuged first at 2,000  g for 20 min to remove debris and apoptotic
bodies. Subsequently, EVs were purified by a 2 h ultracentrifugation
at 100,000  g at 4C (Optima L-90K ultracentrifuge; Beckman
Coulter, Brea, CA, USA). The resulting EVs pellet was resuspended
in RPMI containing 1% DMSO (Sigma-Aldrich, St. Louis, MO,
USA) and stored at 80C. EVs were characterized for size distribu-
tion and quantified by NTA using ZetaView (Particle Metrix GmbH,
Inning am Ammersee, Germany). The quantification of each
preparation of EVs (n = 10) was repeated three times.
Qualitative analysis of EV surface markers was conducted by flow
cytometry using a FACSCalibur instrument and CellQuest software
(Becton Dickinson Bioscience PharMingen, Franklin Lake, NJ,
USA). Because EVs are too small for FACSCalibur analysis, we bound
EVs to latex beads (Aldehyde/Sulfate Latex Beads, 4% w/v, Thermo
Fisher Scientific). Briefly, EVs (about 3  109) were co-incubated
with 5 mL beads for 15 min at room temperature and for 45 min at
4C in a final volume of 100 mL of PBS at pH 7.2, with 0.5%w/v lyoph-Moleculilized powder BSA (Sigma-Aldrich). After incubation, the EVs-beads
solution was washed for 5 min by centrifugation at 2,000  g to
eliminate unbounded EVs.
EVs adsorbed to the beads were divided in different tubes and incu-
bated for 45 min at 4C with the following primary antibodies
(all from Santa Cruz, Dallas, TX, USA): CD63 (1:20, sc-5275), CD9
(1:20, sc-13118), and CD81 (1:50, sc-31234). The EVs-beads solution
was washed to remove unbounded antibodies. Anti-mouse PE and
anti-goat FITC (A-11003 and A-11055, respectively; Thermo Fisher
Scientific) secondary fluorescence antibodies (1: 500) were added to
the tubes and incubated for 20 min at 4C. The adsorbed EVs were
washed and analyzed by flow cytometry. The EVs-beads solution
incubated with secondary antibodies alone was used as negative con-
trol for analysis. The same analysis was conducted with ASCs, previ-
ously permeabilized for 15 min with a solution of 0.1% Triton (v/v) in
PBS. The cells were labeled with the primary antibodies (1:100)
and secondary antibodies (1:1,000) following standard labeling
procedures.58
Transmission Electron Microscopy
TEM of cells and EVs were carried out as previously described.58
Briefly, ASCs were washed in PBS (pH 7.2) fixed in 2.5% (w/v) glutar-
aldehyde with 4% (w/v) freshly prepared formaldehyde in 0.1 M ca-
codylate buffer (pH 7.2) for 24 h and post-fixed in 1% OsO4 (w/v)
plus 0.8% K4Fe(CN)6 (w/v) in 0.1 M cacodylate buffer for 40 min, de-
hydrated in acetone, and embedded in epoxide resin for electron mi-
croscopy analysis. ASC-EVs were adhered onto glow-discharged for-
mvar-coated copper grids 300 mesh (EMS, Hartfield, PA, USA) for
10 min. Grids were subsequently negatively stained with 1% (w/v)
aurothioglucose (USP, Sigma-Aldrich) in water for 30 s, dried with
filter paper, and examined in an electron microscope operating at
120 kV (Tecnai Spirit microscope, Thermo Fisher Scientific).
DOCA-Salt Model
Animal studies were run in accordance with the Brazilian College of
Animal guidelines, with all procedures receiving approval from the
Institutional Committee for Animal Care and Use of the Federal Uni-
versity of Rio de Janeiro (CEUA, certificate 038/15 and A02/16-61-
15). The DOCA-salt model was generated by a modified protocol
from.59 7-week-old male Wistar rats were obtained from the animal
facility of Biomedical Science Institute, University of São Paulo (São
Paulo, Brazil).
After 1 week of acclimatization, animals were anesthetized by intra-
peritoneal injection of xylazine (5 mg/kg; Bayer S.A., São Paulo,
Brazil) and ketamine (50 mg/kg; Cristália, Itapira, Brazil) and under-
went unilateral nephrectomy (left kidney). 1 week later, the nephrec-
tomized animals were randomly divided into 3 cohorts: (1) the
normal salt control-group, which received standard-Na+ diet chow
(0.50% w/w Na+, Rhoster Industria e Comercio, Araçoiaba da Serra,
Brazil), and was injected subcutaneously with vehicle (soybean
oil, 0.1 mL/animal) and weekly i.v. injection of vehicle, starting
from week 2 after nephrectomy (100 mL of PBS plus DMSOar Therapy: Methods & Clinical Development Vol. 16 March 2020 73
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treatment, animal tested n = 9); (2) the high-salt group, which
received high-Na+ diet (1.5% w/w Na+, Rhoster) in combination
with a subcutaneous administration of DOCA (D7000-5G, Sigma-Al-
drich) (8 mg/kg, twice a week in soybean oil) and weekly i.v. injection
of vehicle, starting from week 2 after nephrectomy (100 mL of PBS
plus DMSO 0.2 mg/week/300 gr) (DOCA, n = 16; three animals
died during the treatment, animal tested n = 13); and (3) the high-
salt group that received high-Na+ diet in combination with a subcu-
taneous administration of deoxycorticosterone acetate, and weekly
i.v. injection of ASC-EVs, starting from week 2 after nephrectomy
(1.5  109/week in PBS plus DMSO 0.2 mg/week/~300 gr)
(DOCA-EV, n = 10). A 4th group of Sham-operated rats receiving
standard-Na+ diet was added as control (SHAM, n = 8). Animals
were kept in a 12 h light/dark cycle under controlled temperature
(22C–24C) and humidity (40%–60%), with free access to filtered
water and respective diet ad libitum for 8 weeks after nephrectomy
until sacrifice (from 9 to 17 weeks of age) (Figure 1).
Non-invasive Blood Pressure, Water Intake, and Urine Output
Measurements
SBP andDBPweremeasured by the tail-cuff method (EFF306, Insight
Instruments, Ribeirão Preto, Brazil), which allows repeated and
reliable determinations to be made over a short period in conscious
animals. The animals were kept at 30C ± 2C for 20 min. After
stabilization, blood pressure of each rat was registered by performing
3 consecutive measurements and the final value considered was the
average of these 3 measures. The measurements were conducted
each 1 minute and the animals were run one by one. Blood pressure
was recorded at the same time every week. Animal weight was also
recorded for all the experiments until sacrifice.
Before the surgical procedure (time 0) and on weeks 3, 5, 7, and 9 after
uninephrectomy, rats were individually housed in metabolic cages
provided with water (200 mL/day) and regular or high-salt chow
(25 g/day). In order to reduce physiologic changes induced by envi-
ronment modification, the animals were acclimated in metabolic
cages for 24 h before sample collection.60 Urine output and water
intake were measured within the following 24 h. In addition, a urine
sample was collected and clarified by centrifugation (600  g
for 5 min) for biochemical analysis. At the time of sacrifice, blood
samples (~6 mL) were collected in tubes previously rinsed with
1 mM Na2EDTA and plasma was collected by centrifugation
(2000  g for 10 min). Plasma and urine samples were stored in ali-
quots at 20C. The heart and the kidney were removed, their wet
weights were recorded, and then they were processed for histological
and molecular analysis.
Biochemical Analysis
Creatinine concentrations were measured in urine and plasma sam-
ples by the Jaffe’s reaction method (K016, Bioclin, Belo Horizonte,
Brazil).61 Urinary protein excretion was determined by a colorimetric
assay using a commercial kit (498, Proteinúria-PP, Gold Analisa, Belo
Horizonte, Brazil) and measured as 24 h-protein urinary excretion74 Molecular Therapy: Methods & Clinical Development Vol. 16 March(mg/24 h). Microalbuminuria was measured by immune turbidi-
metric assay (K078, Microalbuminuria, Bioclin). Na+ and K+ concen-
trations were measured by flame photometry (Analyzer, São Paulo,
Brazil) in urine samples, as previous described.62 Creatinine clear-
ance63 (CrC, normalized by body weight), urinary protein/urinary
creatinine (concentration of proteins in the urine in respect to
the concentration of urinary creatinine, mg/g, UP:Cr), and urinary
albumin/urinary creatinine (concentration of albumin in the urine
in respect to the concentration of urinary creatinine, mg/g, UA:Cr)
were then calculated.
Tissue Histology and Immunohistochemical Analyses
The kidneys and hearts were fixed, dehydrated, and embedded in
paraffin as previously described.64 Heart slices (7-mm thick) were
stained with Masson’s trichrome for connective tissue accumulation.
Fibrotic areas were assessed by Picrosirius red staining in both kidney
and heart specimens to evaluate collagen deposition.
Macrophage/monocytes (CD68), PCNA, and the pre-fibrotic marker
a-SMA were detected by immunohistochemistry using the following
mouse monoclonal antibodies on 5 mm-thick paraffin sections: CD68,
MCA341R (1:50, Bio-Rad, Hercules, CA, USA); PCNA, M0879
(1:100, Agilent Technologies); and a-SMA, ab7817 (1:50, Abcam,
Cambridge, UK). Sections were submitted to heat-induced antigen
retrieval by microwave heating at boiling point in 0.01 M Na-citrate
buffer (pH 6.0). For CD68 staining, pre-incubation with 0.1% (w/v)
trypsin solution was added to the protocol. Slides were incubated
overnight in a humid chamber (4C) with the primary antibodies,
and binding was detected by incubation with Nichirei Histofine Rat
Simple Stain anti-mouse secondary antibody (414171F, Tokyo,
Japan) for 1 h at room temperature. Peroxidase activity was detected
with 3,30-diaminobenzidine (K3468 DAB, Agilent Technologies) as
chromogen, and the slides were counterstained with hematoxylin.
Negative controls consisted of sections incubated with an isotype-spe-
cific IgG were added.
The density of CD68 expression in the kidney and heart are given as a
percentage of CD68 immunodetected and expressed as mean ± SEM.
PCNA was determined by the number of positive cells/fields in the
cortical and medullary regions of the kidney. Images were obtained
using an Olympus AX70 microscope (Olympus, Japan), and the
analysis was conducted using the ImageJ software (NIH, Bethesda,
MD, USA) in at least 12 randomly captured photomicrographs.
Histological Score of Kidney Lesions
Kidney sections were examined by a pathologist in a blinded manner.
Paraffin sections were stained with H&E and periodic acid-Schiff
(PAS) and observed under light microscopy for qualitative and
quantitative analysis. Tubulointerstitial injury was scored based on
the following tubule alterations: loss/disruption of brush border in
proximal tubule cells, cellular vacuolization in all nephron segments,
cell death with detachment from basement membrane culminating in
tubular cell desquamation, tubular dilation due to tubular obstruc-
tion, casts accumulation in the tubular space, and later, tubular2020
www.moleculartherapy.orgatrophy due to the loss of viable tubular cells. Glomerular lesions were
scored after the observation of 100 glomeruli (transverse sections)
from each animal in PAS stained sections. Glomerular injury
consisted of capsular thickening, mesangial axis enlargement, and
the presence of glomerulosclerosis (segmental or global). Vascular
damage was characterized by the luminal diminution, myointimal
hyperplasia, hyaline arteriopathy, and fibrinoid necrosis.
Semiquantitative data were obtained from high-quality photomicro-
graphs (2,048  1,536 pixel buffer) using a digital camera (Evolution
VF, Media Cybernetics, Bethesda, MD, USA) connected to Nikon
Eclipse E-800 light microscope and the graphical interface software
Q-capture 2.95.0, version 2.0.5 (Silicon Graphic, Milpitas, CA,
USA). Ten non-overlapping images of vessels (arteriole and artery),
or tubules (kidney cortex, and outer medulla), were randomly ob-
tained with a 40 (tubular profiles) or a 20 (glomerular and
vascular profiles) objective lens from each kidney section stained
with PAS (tubular profiles), or H&E (vascular profiles) (animals/
group: SHAM, n = 4; UNX, n = 9; DOCA, n = 13; DOCA-EV,
n = 10). Histological lesions were graded from 03 as follows: 0,
absence; 0.5, up to 10% injured tubules, glomeruli, vessels, or intersti-
tial area; 1.0, 11%25%; 1.5, 26%45%; 2.0, 46%60%; 2.5, 61%
75%; 3.0, R76%. A histological injury score was produced for each
profile (tubular, vascular, or glomerular) and was obtained by the
sum of all the values of the respective damage parameters analyzed.17
Western Blotting
Kidney cortex extracts were homogenized in radioimmunoprecipita-
tion assay (RIPA) buffer supplemented with protease and phospha-
tase inhibitor cocktail and PMSF (Sigma-Aldrich). Protein content
was determined by the Folin-phenol method,65 using BSA as a stan-
dard. Aliquots of 30 mg proteins were run on 10%–12% SDS-PAGE
under reducing conditions, and western blotting was carried out as
previously described.65 The following primary antibodies were used:
GAPDH, sc-32233 (1:1,000, Santa Cruz); a-SMA, MAB1420
(1:1,000, R&D Systems, Minneapolis, MN, USA); Desmin, ab32362
(1:1,000, Abcam); B cell lymphoma 2 (Bcl2), 2876 (1:1,000, Cell
Signaling Technology, Danvers, MA, USA); and Bcl-2-associated X
(Bax), 2772S (1:500, Cell Signaling Technology). The secondary anti-
bodies were anti-rabbit and anti-mouse IgG-horseradish peroxidase
(HRP) (NA934-1 and NA931, 1:5,000 and 1:10,000, GE Healthcare,
Buckinghamshire, UK). Proteins were detected by chemilumines-
cence using the ECL system (GE Healthcare) and ChemiDoc XRS+
(Bio-Rad). Quantification of western blots was performed with
ImageJ software (NIH).
Microarrays Profile and Quantitative Real-Time PCR
The Absolutely RNAmiRNA Kit (400814, Agilent Technologies) was
used for RNA extraction from renal tissue. The yield of the extracted
RNA was determined spectrophotometrically (Nanodrop-1000,
Thermo Scientific). RNA integrity and quality were evaluated using
RNA 6000 Nano Chip and Agilent 2100 Bioanalyzer (Agilent Tech-
nologies). RNA samples with RNA integrity numbers (RINs) > 8.0
were used for microarray experiments.66MoleculSingle color (Cy3) miRNA Array (8  15k) (for the screening of 780
mature miRNAs) and reagents were used (Agilent Technologies)
using 100 ng of total RNA for the labeling and hybridization proced-
ures. Microarray profile analysis was conducted on a pool of 4
animals/treatment (SHAM, UNX, DOCA, and DOCA-EV) and
were repeated using different experimental groups. An Agilent one-
color spike in kit was used as a positive control to measure both the
labeling and hybridization procedures. Data were analyzed using
the Agilent GeneSpring GX Data software (Agilent Technologies),
where the expressed miRNAs were defined as entities detected in at
least 80% of the values of any of the 4 conditions. Microarray data
have been deposited in the GEO "GEO: GSE139660". Differential
expression was determined by a fold changeR1.5 to define upregu-
lation or downregulation with respect to DOCA-salt treatment. A
pathway enrichment analysis used MetaCore software v.6.35 (Thom-
son Reuters, Toronto, Canada). A Venn diagram was generated using
the online software of Bioinformatics & Evolutionary Genomics.67
Microarrays data were confirmed by quantitative real-time PCR, us-
ing the miRNA 1st Strand Synthesis and miRNA qPCR Master Mix
kits (both from Agilent Technologies). Negative non-polyadenylated
RNA controls and negative cDNA controls (no cDNA) were cycled to
the specificity of the detection. Mature Let-7a was used as miRNA in-
ternal reference after stability and expression test on a panel of repre-
sentative samples. mRNA data analysis used the High Capacity cDNA
Reverse Transcription Kit and the Power SYBR Green PCR Master
Mix (from Life Technologies) in a ViiA 7 Real-Time PCR System
(Life Technologies). The run conditions were as follows: 95C for
10 min, followed by 40 cycles of 30 s at 95C and 1 min at 60C.
Melting curve analysis was added to the run. The sequence-specific
oligonucleotide primers were all obtained from Eurofins Genomics
(Eurofins Brazil, Indaiatuba, Brazil). Negative cDNA controls (no
cDNA) were cycled in parallel with each run. GAPDH was used as
the mRNA internal reference, and the fold expression was calculated
according to the 2-DDCt method,68 using the UNX as reference sample
(UNX = 1). The primers used in quantitative real-time PCR experi-
ments are described in Table S3.Statistical Analysis
Where appropriate, results are expressed as mean ± SEM. Statistical
analysis used one-way ANOVA followed by Tukey’s multiple
comparison test or t test where necessary. Differences were consid-
ered significant at p < 0.05.SUPPLEMENTAL INFORMATION
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